KV Pharmaceutical Smacked With Class-Action Lawsuit

by

comment
Big beard, big problems: KV's former CEO Marc Hermelin - IMAGE VIA
  • Image via
  • Big beard, big problems: KV's former CEO Marc Hermelin
As if KV Pharmaceutical wasn't roiling with enough intrigue already: In addition to criminal convictions, a wave of firings, bickering executives, and legal wrangling, the Bridgeton-based drug company now must defend itself against a class-action lawsuit.

The suit, filed yesterday in federal court, is being brought by folks who purchased KV stock last Spring. The plaintiffs allege that the company was less than up-front about its "financial well-being, business operations, and prospects" at that time.

Specifically, the plaintiffs claim, KV failed to disclose that the FDA hadn't granted the company exclusive distribution rights to Makena -- a hormone injection used by pregnant women to lower the risk of premature birth.

Nor, they allege, did KV level with investors about Makena's $1500 price tag per dosage, and how that would "decrease meaningful demand."

Check out the complaint below. Class Action Complaint v. KV Pharm

Support Local Journalism.
Join the Riverfront Times Press Club

Local journalism is information. Information is power. And we believe everyone deserves access to accurate independent coverage of their community and state. Our readers helped us continue this coverage in 2020, and we are so grateful for the support.

Help us keep this coverage going in 2021. Whether it's a one-time acknowledgement of this article or an ongoing membership pledge, your support goes to local-based reporting from our small but mighty team.

Join the Riverfront Times Club for as little as $5 a month.